Efficacy and Safety of Endoscopic Resection
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03050333 |
Recruitment Status :
Recruiting
First Posted : February 10, 2017
Last Update Posted : February 10, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Endoscopic Resection Gastrointestinal Neoplasms |
Study Type : | Observational |
Estimated Enrollment : | 3000 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | Efficacy and Safety of Endoscopic Resection |
Actual Study Start Date : | April 25, 2013 |
Estimated Primary Completion Date : | December 31, 2022 |
Estimated Study Completion Date : | December 31, 2023 |
- Proportion of complete resections without recurrence [ Time Frame: 6 month post-endoscopic resection ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Female and male patients who are at least 18 years old.
- Clinical indication for endoscopic exam and endoscopic resection
- Patients must freely accept their involvement in this study. They shall give a written informed consent
Exclusion Criteria:
- Patients who do not desire to be included in this study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03050333
Contact: EDUARDO ALBENIZ, MD | edualbeniz@hotmail.com |
Spain | |
Eduardo Albeniz Arbizu | Recruiting |
Pamplona, Navarra, Spain, 31008 | |
Contact: EDUARDO ALBENIZ, MD edualbeniz@hotmail.com | |
Contact: FERRAN CAPDEVILA, PHARMD fcapdevb@navarra.es | |
Principal Investigator: EDUARDO ALBENIZ, MD |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | EDUARDO ALBENIZ, MD, Fundacion Miguel Servet |
ClinicalTrials.gov Identifier: | NCT03050333 |
Other Study ID Numbers: |
ALB-RME-2013-01 |
First Posted: | February 10, 2017 Key Record Dates |
Last Update Posted: | February 10, 2017 |
Last Verified: | February 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site |
Neoplasms Digestive System Diseases Gastrointestinal Diseases |